

EMA/177613/2023

European Medicines Agency decision

P/0176/2023

of 15 May 2023

on the acceptance of a modification of an agreed paediatric investigation plan for dasiglucagon (EMA-002233-PIP01-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0176/2023

of 15 May 2023

on the acceptance of a modification of an agreed paediatric investigation plan for dasiglucagon, (EMA-002233-PIP01-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0220/2018 issued on 19 July 2018, and the decision P/0393/2021 issued on 8 September 2022,

Having regard to the application submitted by Zealand Pharma A/S on 15 December 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 31 March 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for dasiglucagon, solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Zealand Pharma A/S, 11 Sydmarken, 2860 – Søborg, Denmark.

EMA/PDCO/3643/2023
Amsterdam, 31 March 2023

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-002233-PIP01-17-M02

Scope of the application

Active substance(s):

Dasiglucagon

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of hypoglycaemia

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Zealand Pharma A/S

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Zealand Pharma A/S submitted to the European Medicines Agency on 15 December 2022 an application for modification of the agreed paediatric investigation plan as set out in the European Medicines Agency's decision P/0220/2018 issued on 19 July 2018, and the decision P/0393/2021 issued on 8 September 2022.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 30 January 2023.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

1.1. Condition:

Treatment of hypoglycaemia

The request for the waiver applied to:

- the paediatric population from birth to less than 1 year of age;
- solution for injection, subcutaneous use.

The waiver request does not provide evidence to support the following grounds set out in Article 11(1) of Regulation (EC) No 1901/2006 that:

- the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

Because:

- the specific medicinal product may represent a significant therapeutic benefit as the needs are not met.

The waiver request is therefore refused by the PDCO.

2. Paediatric investigation plan

2.1. Condition:

Treatment of hypoglycaemia

2.1.1. Indication(s) targeted by the PIP

Acute treatment of severe hypoglycaemia in children from 0 to less than 18 years of age

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable.
Non-clinical studies	Not applicable.

Clinical studies	Study 1 Blinded, randomised, 3-arm, parallel trial in paediatric patients aged from 6 to less than 18 years of age with Type 1 diabetes mellitus to evaluate the ability of dasiglucagon to increase plasma glucose relative to placebo and GlucaGen. The primary objective is demonstration of superiority of dasiglucagon over placebo. Study 2 Open-label trial in paediatric patients from birth to less than 6 years with Type 1 diabetes mellitus to evaluate the ability of dasiglucagon to increase plasma glucose as well as its safety and PK.
Extrapolation, modelling and simulation studies	Study 3 Population pharmacokinetic (pop-PK) and pharmacokinetic-pharmacodynamic (PKPD) modelling to inform dose finding and optimize the subsequent clinical study in children with hypoglycaemia from 6 to less than 18 years of age (PIP Study 1, ZP4207-17086). Study 4 Population pharmacokinetic (pop-PK) and pharmacokinetic-pharmacodynamic (PKPD) modelling to inform dose finding and optimize the subsequent clinical study in children with hypoglycaemia from birth to less than 6 years of age (PIP Study 2).
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.